The Use of Poly and Acrylamide are Allowing Drugs to Easily Reach Their Target…
FDA Latest Industry Guidance for Liposome Drug Products
Liposome Drug Products
Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation
It provides specific labeling requirements for liposome versus pegylated liposome.
The nonproprietary name of a drug product approved under the Federal Food, Drug, and Cosmetic Act is its established name, which , in most instances , will be the United States
Pharmacopeia (USP) drug product monograph title for that product. If there is no USP monograph for the liposome drug product, you should refer to 21 CFR 299.4, USP General
Chapter <1121> Nomenclature, and the USP Nomenclature Guidelines. The liposome drug product nonproprietary name should include terminology to express that the product is a liposome or a pegylated liposome. Examples:
[DRUG] Liposome Type X [DOSAGE FORM]
[DRUG] Pegylated Liposome Type X [DOSAGE FORM]
Related Posts
- How Surfactant PEG are Helping the Drug Industry
- FDA guidelines to Industry on PEGylated Protein drug immunogenicity
Immune responses to therapeutic protein products may pose problems for both patient safety and product…